 Tonix Pharmaceuticals Holding Corp. NASDAQ: TNXP shares are rallying higher Thursday after the company announced the FDA has granted Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi syndrome. The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin. 